BACKGROUND AND AIMS: MicroRNAs [miRNAs] have emerged as important regulators in inflammatory bowel disease [IBD]. This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls [HCs]. METHODS: A cohort of Crohn's disease [CD] and ulcerative colitis [UC] patients and HCs was prospectively accrued. Total RNA was extracted from peripheral blood mononuclear cells for all subjects. miRNA expression was measured using NanoString technologies. The subjects were stratified according to disease activity and location. Statistical significance was assessed per miRNA across outcomes and corrected for multiple testing. miRNA regulation of transcription of important results was confirmed in vitro by a dual luciferase reporter assay and autophagy function was evaluated using immunofluorescence imaging of LC3 puncta in HeLa cells. RESULTS: In total, 120 subjects were enrolled. Seventy-four miRNAs were differentially expressed across CD, UC and HCs. Comparing quiescent CD [CDq] with HCs we found ten miRNAs upregulated in CDq. When comparing colonic CD [CCD] to UC, seven miRNAs were upregulated in CCD. The most differentially expressed miRNA in CCD vs UC was miR-874-3p, and we showed its possible utility as a biomarker of differential diagnosis. We showed miR-874-3p targets ATG16L1 and reduces its expression in vitro. An miR-874-3p mimic dysregulates autophagy by a reduction of LC3 in vitro. CONCLUSIONS: We identified unique miRNA signatures expressed in distinct IBD phenotypes. These associations highlight pathways dysregulated by aberrant miRNA expression, revealing possible mechanisms underlying the pathophysiology of IBD, but also suggest a cluster of miRNAs as readily accessible biomarkers to aid in differential diagnosis.
BACKGROUND AND AIMS: MicroRNAs [miRNAs] have emerged as important regulators in inflammatory bowel disease [IBD]. This study investigated differential expression of miRNAs across clinical phenotypes in a well-characterized cohort of IBD patients and healthy controls [HCs]. METHODS: A cohort of Crohn's disease [CD] and ulcerative colitis [UC] patients and HCs was prospectively accrued. Total RNA was extracted from peripheral blood mononuclear cells for all subjects. miRNA expression was measured using NanoString technologies. The subjects were stratified according to disease activity and location. Statistical significance was assessed per miRNA across outcomes and corrected for multiple testing. miRNA regulation of transcription of important results was confirmed in vitro by a dual luciferase reporter assay and autophagy function was evaluated using immunofluorescence imaging of LC3 puncta in HeLa cells. RESULTS: In total, 120 subjects were enrolled. Seventy-four miRNAs were differentially expressed across CD, UC and HCs. Comparing quiescent CD [CDq] with HCs we found ten miRNAs upregulated in CDq. When comparing colonic CD [CCD] to UC, seven miRNAs were upregulated in CCD. The most differentially expressed miRNA in CCD vs UC was miR-874-3p, and we showed its possible utility as a biomarker of differential diagnosis. We showed miR-874-3p targets ATG16L1 and reduces its expression in vitro. An miR-874-3p mimic dysregulates autophagy by a reduction of LC3 in vitro. CONCLUSIONS: We identified unique miRNA signatures expressed in distinct IBD phenotypes. These associations highlight pathways dysregulated by aberrant miRNA expression, revealing possible mechanisms underlying the pathophysiology of IBD, but also suggest a cluster of miRNAs as readily accessible biomarkers to aid in differential diagnosis.
Authors: Rogerio B Kato; Bhaskar Roy; Fabiola S De Oliveira; Emanuela P Ferraz; Paulo T De Oliveira; Austin G Kemper; Mohammad Q Hassan; Adalberto L Rosa; Marcio M Beloti Journal: J Cell Physiol Date: 2014-11 Impact factor: 6.384
Authors: Feng Wu; Simin Zhang; Themistocles Dassopoulos; Mary L Harris; Theodore M Bayless; Stephen J Meltzer; Steven R Brant; John H Kwon Journal: Inflamm Bowel Dis Date: 2010-10 Impact factor: 5.325
Authors: N Nohata; T Hanazawa; N Kikkawa; D Sakurai; L Fujimura; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; M Nakagawa; A Katayama; Y Harabuchi; Y Okamoto; N Seki Journal: Br J Cancer Date: 2011-08-16 Impact factor: 7.640
Authors: Florence Allantaz; Donavan T Cheng; Tobias Bergauer; Palanikumar Ravindran; Michel F Rossier; Martin Ebeling; Laura Badi; Bernhard Reis; Hans Bitter; Matilde D'Asaro; Alberto Chiappe; Sriram Sridhar; Gonzalo Duran Pacheco; Michael E Burczynski; Denis Hochstrasser; Jacky Vonderscher; Thomas Matthes Journal: PLoS One Date: 2012-01-20 Impact factor: 3.240
Authors: Simonas Juzenas; Matthias Hübenthal; Carl Mårten Lindqvist; Robert Kruse; Tim Alexander Steiert; Frauke Degenhardt; Dominik Schulte; Susanna Nikolaus; Sebastian Zeissig; Daniel Bergemalm; Sven Almer; Henrik Hjortswang; Francesca Bresso; Nina Strüning; Juozas Kupcinskas; Andreas Keller; Wolfgang Lieb; Philip Rosenstiel; Stefan Schreiber; Mauro D'Amato; Jonas Halfvarson; Georg Hemmrich-Stanisak; Andre Franke Journal: J Crohns Colitis Date: 2022-08-04 Impact factor: 10.020
Authors: Reza Yarani; Ali Shojaeian; Oana Palasca; Nadezhda T Doncheva; Lars Juhl Jensen; Jan Gorodkin; Flemming Pociot Journal: Front Immunol Date: 2022-06-06 Impact factor: 8.786